<DOC>
	<DOCNO>NCT00452595</DOCNO>
	<brief_summary>To evaluate long-term safety desvenlafaxine sustain release ( DVS-233SR ) open-label treatment outpatient major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Study Evaluating DVS-233 Treatment Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients . Men woman age 18 75 year . Women childbearing potential must negative serum pregnancy test result screening . Sexually active individual participate study must use medically acceptable form contraception study least 15 day last dose test article . Subjects must primary diagnosis MDD base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) , single recurrent episode , without psychotic feature , study day 1 . If allowable psychiatric diagnosis present , MDD must predominant psychiatric disorder present . ( See Exclusion Criterion 6 psychiatric diagnosis allowable . ) Depressive symptom least 30 day screen visit . Subjects symptoms depression judge investigator require longterm treatment ( i.e. , 6 month longer ) antidepressant drug . Other inclusion applies . Treatment DVS233 SR time past . Treatment venlafaxine ( immediate release [ IR ] extend release [ ER ] ) within 90 day study day 1 . Known hypersensitivity venlafaxine ( IR ER ) . Significant risk suicide base clinical judgment , include common suicidal thought , suicide consider possible solution , even without specific plan intention . Women pregnant , breastfeeding , plan become pregnant study . Current ( within 12 month baseline ) psychoactive substance abuse dependence ( include alcohol ) , manic episode , posttraumatic stress disorder , obsessivecompulsive disorder , lifetime diagnosis bipolar psychotic disorder assess modify Mini International Neuropsychiatric Interview ( MINI ) . Current ( within 12 month baseline ) generalize anxiety disorder , panic disorder , social anxiety disorder assess modify MINI consider investigator primary , cause high degree distress impairment MDD . Presence ( within 12 month baseline ) clinically important personality disorder ( antisocial , schizotypal , histrionic , borderline , narcissistic ) . Depression associate presence organic mental disorder due general medical condition neurologic disorder . History seizure disorder single childhood febrile seizure . Other exclusion applies .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>